Research Analysts Set Expectations for CRBP Q3 Earnings

Key Points

• HC Wainwright lowered its Q3 2026 EPS estimate for Corbus Pharmaceuticals to a loss of $1.57 per share from $1.26, while maintaining a Buy rating and a $35 price target.
• Corbus reported a quarterly loss of $1.81 per share, missing the $1.26 consensus estimate by $0.55; the analyst also reduced full-year loss forecasts through 2029 and now expects only $0.15 EPS in 2030.
• Analyst sentiment remains moderately bullish, with eight Buy ratings and two Sell ratings, but recent price-target cuts, a 7% stock decline, and insider selling add to investor caution.

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Free Report) - Stock analysts at HC Wainwright lowered their Q3 2026 earnings per share (EPS) estimates for shares of Corbus Pharmaceuticals in a research note issued to investors on Friday, August 7th. HC Wainwright analyst A. Maldonado now forecasts that the biopharmaceutical company will post earnings per share of ($1.57) for the quarter, down from their previous estimate of ($1.26). HC Wainwright currently has a "Buy" rating and a $35.00 target price on the stock. The consensus estimate for Corbus Pharmaceuticals' current full-year earnings is ($4.87) per share. HC Wainwright also issued estimates for Corbus Pharmaceuticals' Q4 2026 earnings at ($1.50) EPS, FY2026 earnings at ($6.11) EPS, FY2027 earnings at ($6.83) EPS, FY2028 earnings at ($5.56) EPS, FY2029 earnings at ($2.07) EPS and FY2030 earnings at $0.15 EPS.

Corbus Pharmaceuticals (NASDAQ:CRBP - Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported ($1.81) earnings per share for the quarter, missing the consensus estimate of ($1.26) by ($0.55).

• Corbus Pharmaceuticals NASDAQ: CRBP Gives a Bold Buy Signal

CRBP has been the subject of several other research reports. Wall Street Zen lowered shares of Corbus Pharmaceuticals from a "sell" rating to a "strong sell" rating in a research report on Saturday. Weiss Ratings reiterated a "sell (d-)" rating on shares of Corbus Pharmaceuticals in a report on Friday, July 17th. Guggenheim reissued a "buy" rating on shares of Corbus Pharmaceuticals in a research note on Tuesday, May 26th. Mizuho reduced their target price on shares of Corbus Pharmaceuticals from $44.00 to $34.00 and set an "outperform" rating for the company in a report on Tuesday, June 23rd. Finally, Wedbush decreased their price target on shares of Corbus Pharmaceuticals from $38.00 to $30.00 and set an "outperform" rating on the stock in a research report on Wednesday, May 27th. Eight equities research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $41.12.

Corbus Pharmaceuticals Trading Down 7.0%

Shares of Corbus Pharmaceuticals stock opened at $9.46 on Tuesday. The company's 50-day moving average price is $8.76 and its two-hundred day moving average price is $9.06. Corbus Pharmaceuticals has a 52 week low of $7.12 and a 52 week high of $20.56. The stock has a market cap of $175.29 million, a PE ratio of -1.53 and a beta of 2.59.

Insider Activity

In other Corbus Pharmaceuticals news, Director John Kenneth Jenkins sold 4,800 shares of the business's stock in a transaction on Wednesday, June 10th. The shares were sold at an average price of $7.91, for a total transaction of $37,968.00. Following the sale, the director directly owned 3,833 shares of the company's stock, valued at $30,319.03. The trade was a 55.60% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Yuval Cohen sold 17,000 shares of the firm's stock in a transaction on Friday, August 7th. The stock was sold at an average price of $10.08, for a total value of $171,360.00. Following the completion of the sale, the chief executive officer directly owned 157,316 shares of the company's stock, valued at approximately $1,585,745.28. This trade represents a 9.75% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 38,238 shares of company stock valued at $365,393 in the last 90 days. Company insiders own 3.50% of the company's stock.

Hedge Funds Weigh In On Corbus Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of CRBP. Persistent Asset Partners Ltd purchased a new stake in shares of Corbus Pharmaceuticals in the fourth quarter worth approximately $54,000. Virtu Financial LLC purchased a new position in Corbus Pharmaceuticals during the fourth quarter valued at approximately $88,000. Barclays PLC grew its position in Corbus Pharmaceuticals by 280.0% during the fourth quarter. Barclays PLC now owns 14,758 shares of the biopharmaceutical company's stock valued at $120,000 after purchasing an additional 10,874 shares in the last quarter. ADAR1 Capital Management LLC acquired a new position in Corbus Pharmaceuticals in the 3rd quarter valued at approximately $129,000. Finally, Bank of America Corp DE increased its stake in Corbus Pharmaceuticals by 53,592.3% in the 1st quarter. Bank of America Corp DE now owns 13,960 shares of the biopharmaceutical company's stock valued at $131,000 after buying an additional 13,934 shares during the period. Hedge funds and other institutional investors own 64.64% of the company's stock.

Key Corbus Pharmaceuticals News

Here are the key news stories impacting Corbus Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating and a $35 price target, implying substantial potential upside from recent trading levels despite reducing its earnings forecasts. Analysts continue to view Corbus’ pipeline, including lenabasum for inflammatory and fibrotic diseases, as a potential long-term catalyst. HC Wainwright Cuts Corbus Pharmaceuticals Price Target
• Neutral Sentiment: Institutional ownership remains high at approximately 64.6%, with several investment firms increasing their positions in the latest reported quarter. However, these holdings are based on historical filings and may not reflect current positioning.
• Negative Sentiment: HC Wainwright materially lowered its EPS outlook across multiple years: 2026 to -$6.11 from -$4.99, 2027 to -$6.83 from -$5.66, 2028 to -$5.56 from -$4.58, and 2029 to -$2.07 from -$1.13. Its 2030 forecast was reduced to just $0.15 from $1.29, while third- and fourth-quarter 2026 loss estimates also widened.
• Negative Sentiment: Analysts have recently reduced price targets, including HC Wainwright to $35 from $40 and Oppenheimer to $48 from $52. Although both firms retain bullish ratings, the cuts suggest lower near-term expectations. Oppenheimer Cuts Corbus Pharmaceuticals Price Target
• Negative Sentiment: Insider selling adds to investor caution. CEO Yuval Cohen sold 17,000 shares and CFO Sean Moran sold 12,000 shares at an average of $10.08, reducing their direct holdings by approximately 9.75% and 12.41%, respectively. Sean Moran Sells Corbus Pharmaceuticals Stock
• Negative Sentiment: Corbus’ latest quarterly results showed a loss of $1.81 per share, wider than the $1.26 analyst consensus, reinforcing concerns about ongoing cash burn and the path to profitability.

Corbus Pharmaceuticals Company Profile

Corbus Pharmaceuticals Holdings, Inc is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of therapeutic candidates for rare, life-threatening inflammatory and fibrotic diseases. The company's lead investigational therapy, lenabasum, is a synthetic, oral cannabinoid receptor type 2 (CB2) agonist designed to resolve chronic inflammation by harnessing the body's innate resolution pathways. Corbus operates by advancing small-molecule compounds through preclinical and clinical studies to address unmet medical needs in autoimmune and inflammatory disorders.

Lenabasum is currently under evaluation in a Phase 3 clinical trial for diffuse cutaneous systemic sclerosis (dcSSc) and in a Phase 2 study for cystic fibrosis–related inflammation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source